ArticleCureus2025
Reversible Dementia With Hypereosinophilia: An Intricate Connection.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypereosinophilic syndrome (HES) is a rare group of disorders characterized by elevated eosinophil levels, leading to tissue infiltration and damage. Neurological complications are observed in over half of the patients. This case study discusses a 45-year-old male patient diagnosed with HES and rapidly progressive dementia. The patient presented with difficulties in routine tasks, attention deficits, memory loss, and frontal headaches lasting one year. His medical history included allergic rhinitis and eczematoid skin lesions. General and neurological examinations revealed deficits in higher mental functions without other abnormalities. Laboratory tests showed significant eosinophilia, and magnetic resonance imaging (MRI) of the brain indicated diffuse cortical atrophy and periventricular hyperintensities. The diagnosis of HES was supported by clinical and laboratory findings. The case highlights the importance of considering HES in patients with unexplained neurological symptoms and eosinophilia to prevent irreversible organ damage. Early recognition and appropriate management are crucial for improving patient outcomes. This study underscores the need for further research to understand HES's pathophysiology and develop targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.